Nalaganje...
Targeted agents for second-line treatment of advanced hepatocellular carcinoma
Over the past ten years, sorafenib, a multikinase inhibitor, has been the standard of care for patients with unresectable hepatocellular carcinoma (HCC) and well-preserved liver function. Recently, lenvatinib, a different multikinase inhibitor, was shown to be non-inferior to sorafenib, in terms of...
Shranjeno v:
| izdano v: | World J Gastrointest Oncol |
|---|---|
| Main Authors: | , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Baishideng Publishing Group Inc
2019
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6815920/ https://ncbi.nlm.nih.gov/pubmed/31662820 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4251/wjgo.v11.i10.788 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|